잠시만 기다려 주세요. 로딩중입니다.

Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation

Chonnam Medical Journal 2020년 56권 1호 p.6 ~ 11
 ( Yoon So-My ) - Chonnam National University Medical School Department of Pharmacology

엄광현 ( Eom Gwang-Hyeon ) - Chonnam National University Medical School Department of Pharmacology

Abstract


Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells incapacitate the normal cell-mediated immune system by expressing immune modulation ligands such as programmed death (PD) ligand 1, the B7 molecule, or secreting activators of immune modulators. Chimeric antigen receptor (CAR) T cells were originally designed to target cancer cells. Engineered approaches allow CAR T cells, which possess a simplified yet specific receptor, to be easily activated in limited situations. CAR T cell treatment is a derivative of the antigen-antibody reaction and can be applied to various diseases. In this review, the current successes of CAR T cells in cancer treatment and the therapeutic potential of CAR T cells are discussed.

키워드

CAR T cell; Neoplasms; T-Lymphocytes; Combined Modality Therapy; Ligands
원문 및 링크아웃 정보
  
등재저널 정보